Keywords
Clopidogrel
Acute coronary syndrome
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To compare clopidogrel and ticagrelor in the setting of acute coronary syndrome, seeking to understand the main benefits and adverse effects of the two drugs, in order to conclude which medication has the best risk-benefit. Methods: The methodology of this work proposes a compilation of searches made in PubMed and the Virtual Health Library; 19 articles were selected for the study of results. The descriptors were “clopidogrel”, “ticagrelor” and “acute coronary syndrome”, all of which were present in the “title” field. Results: In 11 of the articles analyzed, ticagrelor was superior, taking into account benefits such as target vessel revascularization and consequent survival. Adverse effects such as bleeding and dyspnea were also analyzed, with a significant difference in specific groups, such as the elderly and diabetics. Thus, through the analysis of the studies, it was noted a greater effectiveness in the use of ticagrelor, linked to a greater risk of bleeding in certain cases. Final considerations: In the present study, the superiority of ticagrelor in anti-platelet aggregation was observed, and there is a need to consider its use for some groups, due to a greater chance of adverse effects, in which cases, the use of clopidogrel is preferable.
References
ARORA S, et al. Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD, Journal of the American College of Cardiology, 2019; 73(19): 2454–2464.
BHATT D, et al. REVERSE-IT: Effect of Bentracimab on Platelet Inhibition and Hemostasis in Patients on Ticagrelor with Major Bleeding or Requiring Urgent Procedures on Behalf of the REVERSE-IT Investigators. Disponível em: https://www.acc.org/-/media/Clinical/PDF-Files/Approved-PDFs/2021/11/01/AHA21/15Nov/1130amET-REVERSE-IT-aha-2021.pdf. Acessado em: 15 de Outubro de 2022.
BONOW R. Braynwald Tratado de Doenças Cardiovasculares. 10ª ed. Rio de Janeiro: Guanabara Koogan, 2017; 53.
CAIAZZO G, et al. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome, Circ Cardiovasc Interv, 2014; 104-12.
CHEN I-CHIH, et al. Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study, Journal of the Chinese Medical Association, 2016; 79(10): 521–530.
CHEN Z. M, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (London, England), 2005; 366(9497): 1607–21.
CHO JY, et al. Factors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial, Journal of the American Heart Association, 2021; 10: 7.
GIMBEL M, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial, The Lancet, 2020; 395(10233): 1374–1381.
GOTO S, et al. Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients with Acute Coronary Syndrome – Randomized, Double-Blind, Phase III PHILO Study –, Circulation Journal, 2015; 79(11): 2452–2460.
HE P, et al. Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes, Cardiovascular Therapeutics, 2021; 2021: 1–9.
JAMES S, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial, European heart journal, 2010; 31(24): 3006–16.
JEONG YJ, et al. Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography, American Heart Journal, 2020; 222: 121–130.
KANG HJ, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial, American Heart Journal, 2015; 169(6): 899-905.e1.
LINDHOLM D, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial, European Heart Journal, 2014; 35(31): 2083–2093.
LIU GZ, et al. Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity, European Journal of Clinical Pharmacology, 2019; 1059-1068.
MARIAN M. J, et al. Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial. J of the American Heart Association, 2019; 8(23): e012844.
MOON H, et al. Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome, Health and Quality of Life Outcomes, 2021; 19: 1.
NICOLAU JC, et al. Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST, Arq. Bras. Cardiol, 2021; 117(1): 181-264.
PARK K, et al. Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices, Circulation. Cardiovascular Interventions, 2019; 12(10): e008105.
PATEL M. R, et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial, European Journal of Preventive Cardiology, 2015; 22(6): 734–742.
QADERDAN K, et al. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70years and older—rationale and design of the POPular AGE study, American Heart Journal, 2015; 170(5): 981-985.e1.
SABATINE M. S. et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation, New England Journal of Medicine, 2005; 352(12): 1179–1189.
SCHNORBUS B, et al. Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study, European Heart Journal, 2020.
SCHNORBUS B, et al. Effects of Clopidogrel, Prasugrel and Ticagrelor on Microvascular Function and Platelet Reactivity in Patients with Acute Coronary Syndrome Undergoing Coronary Artery Stenting. A Randomized, Blinded, Parallel Group Trial. Frontiers in Cardiovascular Medicine, 2021; 8: 780605.
UNVERDORBEN M, et al. Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics, International Journal of Cardiology, 2016; 202: 167–173.
WALLENTIN L, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes, New England Journal of Medicine, 2009; 361(11): 1045–1057.
WALLENTIN, L, et al. Biomarkers in Relation to the Effects of Ticagrelor in Comparison with Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed with or Without In-Hospital Revascularization, Circulation, 2014; 129(3): 293–303.
WOLF D e LEY K. Immunity and Inflammation in Atherosclerosis. Circulation Research, 2019; 124(2): 315–327.
YAO Y, et al. Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease, Chinese Medical Journal, 2019; 132(19): 2292–2299.
YUSUF S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, The New England Journal of Medicine, 2001; 345(7): 494-502.